Skip to main content
. 2021 Jul 30;12:703006. doi: 10.3389/fneur.2021.703006

Table 1.

Demographic information and symptom prevalence.

VSS patients ( n = 125)
Number Percentage
Age (mean, SD) 31.3, 10.4
Female (male) 63 (62) 50.4% (49.6%)
Lifelong VSS 45 36%
Later onset VSS: 80 64%
 Age of onset (mean, SD) 22.4, 9.8
 VSS duration (mean, SD) 9.7, 9.9
VSS intensity (mean, SD) 3.7, 1.3
VSS disruptiveness (mean, SD) 3.6, 1.6
VSS impact on quality of life (mean, SD) 3.7, 1.7
Migraine 61 48.8%
Family history of migraine 66 52.8%
Relative with VSS 5 4%
Visual symptoms
Palinopsia: afterimages 108 86.4%
Palinopsia: trailing 66 52.8%
Nyctalopia 88 70.4%
Photophobia 58 46.4%
Floaters 113 90.4%
Blue field entoptic phenomena 91 72.8%
Halos 83 66.4%
Number of visual symptoms (mean, SD) 5.4, 1.8
Non-visual sensory symptoms
Tinnitus 97 77.6%
Tremor 43 34.4%
Paraesthesia 59 47.2%
Dizziness 44 35.2%
Other symptoms
Neck pain 63 50.4%
Irritability 70 56%
Concentration problems 99 79.2%
Depersonalisation 45 44.1%
Derealization 31 30.4%
Previous or current anxiety disorder 56 44.8%
Previous or current depressive disorder 48 38.4%